Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT06360120

Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke

Led by Kafrelsheikh University · Updated on 2025-09-05

600

Participants Needed

1

Research Sites

77 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Along with the current clinical trial, the impact of adding atorvastatin or rosuvastatin in the first 24 hours on the clinical outcomes of first-ever large-vessel ischemic stroke patients treated with clopidogrel assessed through NIHSS, mRS, and possible adverse effects.

CONDITIONS

Official Title

Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Males and females aged 18 to 75 years
  • First-ever large-vessel acute ischemic stroke
Not Eligible

You will not qualify if you...

  • Allergy to any studied drugs
  • Clinical seizures as part of stroke
  • Major organ failure
  • Malignancies
  • Myocardial infarction within past 6 weeks
  • Regular use of antiplatelet or anticoagulant drugs in previous week
  • Minor stroke (NIHSS 2 3) or severe stroke (NIHSS 25 25)
  • Spontaneous resolution of symptoms before imaging
  • History of central nervous system disorders (e.g., multiple sclerosis, epilepsy, meningioma)
  • Planned carotid, cerebrovascular, or coronary revascularization within 7 days after randomization
  • Cardioembolic stroke before or after treatment
  • Clinical atrial fibrillation
  • Gastrointestinal bleeding sources such as peptic ulcers
  • Recurrent stroke based on history or MRI
  • Blood glucose less than 50 or greater than 400 mg/dL
  • Platelet count less than 100,000
  • International normalized ratio greater than 1.4
  • Prothrombin time greater than 18
  • Regular use of drugs affecting clopidogrel metabolism (e.g., proton pump inhibitors, ketoconazole, certain calcium channel blockers, rifampin)
  • Pregnant or lactating females
  • Venous infarction
  • Ischemic infarction secondary to hypoperfusion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Kafr Elsheikh University Hospital

Kafr ash Shaykh, Egypt, 33511

Actively Recruiting

Loading map...

Research Team

M

mohamed G. Zeinhom, MD

CONTACT

S

sherihan R. ahmed, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here